Taiwanese chipmaker TASC targets 2027 growth with InP optical chips, glucose sensors nearing mass production

TASC's InP optical chip validation is not a standalone milestone—it is the downstream echo of AI interconnect demand cascading into III-V compound material layers. The 800G-to-1.6T transition doubles per-port EML chip consumption, carving a narrow window for second-tier suppliers outside the Lumentum-Coherent duopoly. Yet Broadcom and Marvell's aggressive silicon-photonics push is eroding InP's share in short-reach applications. If TASC fails to lock in hyperscaler production certification by end-2026, its cautious 2027 outlook collapses into an inventory cycle. On compliance, InP single-crystal ingots and epi-wafer equipment sit in the export-control grey zone. Manufacturers in Taiwan, China face tightening upstream material provenance audits, while compressed certification timelines from Western OEMs squeeze the ramp window tighter than modeled. The glucose sensor pivot, seemingly a diversification play, actually hinges on MEMS-bio-compatibility packaging yield—a far steeper moat than the product narrative suggests. The 12-to-24-month tail: AI optical interconnect capex has not peaked, but the InP-versus-SiPh route war will reach a phase decision around Q3 2026. That inflection triggers a structural repricing of second-tier InP suppliers' bargaining power, and TASC's positioning at that moment determines whether it becomes a qualified second source or a niche legacy player.